AU742970C - Method of suppressing beta-amyloid-related changes in Alzheimer's disease - Google Patents

Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Info

Publication number
AU742970C
AU742970C AU17099/99A AU1709999A AU742970C AU 742970 C AU742970 C AU 742970C AU 17099/99 A AU17099/99 A AU 17099/99A AU 1709999 A AU1709999 A AU 1709999A AU 742970 C AU742970 C AU 742970C
Authority
AU
Australia
Prior art keywords
disease
amyloid
mammal
administration
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU17099/99A
Other languages
English (en)
Other versions
AU742970B2 (en
AU1709999A (en
Inventor
Dennis J. Selkoe
Howard L. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland UC
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU742970(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of AU1709999A publication Critical patent/AU1709999A/en
Application granted granted Critical
Publication of AU742970B2 publication Critical patent/AU742970B2/en
Priority to AU27727/02A priority Critical patent/AU781126B2/en
Assigned to NEURALAB LIMITED reassignment NEURALAB LIMITED Alteration of Name(s) in Register under S187 Assignors: BRIGHAM AND WOMEN'S HOSPITAL
Publication of AU742970C publication Critical patent/AU742970C/en
Assigned to ELAN PHARMA INTERNATIONAL LIMITED reassignment ELAN PHARMA INTERNATIONAL LIMITED Alteration of Name(s) in Register under S187 Assignors: NEURALAB LIMITED
Assigned to JANSSEN ALZHEIMER IMMUNOTHERAPY reassignment JANSSEN ALZHEIMER IMMUNOTHERAPY Alteration of Name(s) in Register under S187 Assignors: ELAN PHARMA INTERNATIONAL LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Engine Equipment That Uses Special Cycles (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU17099/99A 1997-12-03 1998-12-03 Method of suppressing beta-amyloid-related changes in Alzheimer's disease Expired AU742970C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU27727/02A AU781126B2 (en) 1997-12-03 2002-03-28 Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6721997P 1997-12-03 1997-12-03
US60/067219 1997-12-03
US7969798P 1998-03-27 1998-03-27
US60/079697 1998-03-27
PCT/US1998/025694 WO1999027949A1 (en) 1997-12-03 1998-12-03 METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU27727/02A Division AU781126B2 (en) 1997-12-03 2002-03-28 Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Publications (3)

Publication Number Publication Date
AU1709999A AU1709999A (en) 1999-06-16
AU742970B2 AU742970B2 (en) 2002-01-17
AU742970C true AU742970C (en) 2003-03-20

Family

ID=26747618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17099/99A Expired AU742970C (en) 1997-12-03 1998-12-03 Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Country Status (8)

Country Link
EP (1) EP1033998B1 (zh)
JP (2) JP2002511385A (zh)
AT (1) ATE306931T1 (zh)
AU (1) AU742970C (zh)
CA (1) CA2312475C (zh)
DE (2) DE1033998T1 (zh)
ES (1) ES2253839T3 (zh)
WO (1) WO1999027949A1 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (en) 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1033998B1 (en) * 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CN1249085C (zh) * 2000-05-22 2006-04-05 纽约大学 诱导对β淀粉状蛋白和淀粉状蛋白沉积物的免疫反应、与β淀粉状蛋白同源的免疫源性但非淀粉状蛋白源性合成肽
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
AU2002357007A1 (en) 2001-11-21 2003-06-10 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
SI2004688T2 (sl) 2006-03-23 2014-05-30 Bioarctic Neuroscience Ab Izboljšana protofibrilno selektivna protitelesa in njihova uporaba
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2013012811A2 (en) 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
WO2013013056A1 (en) 2011-07-19 2013-01-24 New York University Method for treating amyloid disease
JP2016503410A (ja) * 2012-11-09 2016-02-04 スリーイー セラピューティクス コーポレイション３Ｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｘ線造影剤組成物およびそれを使用して炎症関連症状を治療する方法
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
CA2081482C (en) * 1990-04-27 2000-11-21 Ellis L. Kline Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
WO1995031996A1 (en) * 1994-05-25 1995-11-30 Milkhaus Lab Materials and methods for treatment of plaquing diseases
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
WO1997018855A1 (en) * 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
JPH09208485A (ja) * 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
EP1033998B1 (en) * 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease

Also Published As

Publication number Publication date
CA2312475A1 (en) 1999-06-10
JP2002511385A (ja) 2002-04-16
EP1033998B1 (en) 2005-10-19
WO1999027949A1 (en) 1999-06-10
ATE306931T1 (de) 2005-11-15
EP1033998A1 (en) 2000-09-13
DE69831971T2 (de) 2006-07-06
WO1999027949A9 (en) 1999-09-10
ES2253839T3 (es) 2006-06-01
JP2010215627A (ja) 2010-09-30
CA2312475C (en) 2010-08-03
DE69831971D1 (de) 2006-03-02
DE1033998T1 (de) 2001-05-23
AU742970B2 (en) 2002-01-17
EP1033998A4 (en) 2003-06-04
AU1709999A (en) 1999-06-16

Similar Documents

Publication Publication Date Title
AU742970C (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
JP3712260B2 (ja) 自己免疫疾患のバイスタンダー抑制
JP2548056B2 (ja) Ｉ型糖尿病に係る自己免疫疾患の抑制および予防用製剤
JP4216342B2 (ja) コポリマー１の摂取又は吸入を通じての多発性硬化症の治療
US5720955A (en) Method of treating rheumatoid arthritis with soluble collagen
WO1994007520A1 (en) Method of treating rheumatoid arthritis with type ii collagen
WO1994007520A9 (en) Method of treating rheumatoid arthritis with type ii collagen
JP2001511134A (ja) メトトレキサートと組合せる耐性化を用いる自己免疫疾患の治療
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
US20010007758A1 (en) Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines
JPH09511745A (ja) 経口寛容および／またはタイプｉインターフェロンを用いた自己免疫疾患の治療
US6812205B2 (en) Suppression of vascular disorders by mucosal administration of heat shock protein peptides
WO2007028133A2 (en) Treatment and prevention of vascular dementia
AU781126B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
CA2410563C (en) Methods for preventing strokes by inducing tolerance to e-selectin
JP3845447B2 (ja) タイプ▲ｉｉ▼コラーゲンによるリウマチ性関節炎治療方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEURALAB LIMITED

Free format text: FORMER OWNER WAS: BRIGHAM AND WOMEN'S HOSPITAL

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20020702

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20020912

MK14 Patent ceased section 143(a) (annual fees not paid) or expired